Early Detection Research Network

TMPRSS2:ERG

Aliases:
This biomarker is also known as:
  • T2S:ERG,
  • TMPRSS2:ERG,

Description…

TMPRSS2:ERG gene fusions are a common genetic event in prostate cancer. These fusions are specific for prostate cancer and have also been observed in precursor lesions. Since TMPRSS2:ERG fusions are not seen in every prostate cancer, their utility is in assays combined with other biomarkers, such as PCA3.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Curated
Type: Gene
HGNC Name:

The following organs have data associated with this biomarker…

Attributes

Phase: Two
QA State: Curated

Overview

TMPRSS2:ERG urine assay for prostate cancer detection is in studies in CLIA lab and is undergoing phase 3 validation.

Performance Comment

The combined measurement of PCA3 and TMPRSS2:ERG in urine outperformed serum PSA for prostate cancer diagnosis. The detection of TMPRSS2:ERG fusion in urine has greater than 90% specificity and 94% positive predictive value for prostate cancer detection. Increased TMPRSS2:ERG transcript expression can be a predictor of prostate cancer. A multiplexed model including seven biomarkers (AMACR, ERG, GOLPH2, PCA3, SPINK1, TFF3, TMPRSS2:ERG) outperforms serum PSA or PCA3 alone.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.